Jonathan Licht

Jonathan D. Licht, M.D., is an internationally recognized physician-scientist and medical oncologist whose work focuses on blood and other cancers and on developing innovative therapies. He is president and chief scientific officer of Van Andel Institute and previously directed the University of Florida Health Cancer Institute, leading it to National Cancer Institute designation in 2023. His prior roles include chief of Hematology/Oncology at both the Icahn School of Medicine at Mount Sinai and Northwestern University. His research on aberrant gene regulation and epigenetic mechanisms in leukemia, lymphoma, multiple myeloma and melanoma has been funded by the National Cancer Institute for more than 30
years, supported by multiple R01s, major foundation grants and long-standing support from Blood Cancer United and the Myeloma Solutions Fund. He has authored over 240 publications with more than 37,000 citations and has treated patients with acute leukemia and multiple myeloma.